

Mereo BioPharma Group plc  
Fourth Floor  
One Cavendish Place  
London W1G 0QF  
United Kingdom

May 21, 2024

**VIA EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Division of Corporation Finance  
Office of Life Sciences  
Re: Mereo BioPharma Group plc  
Registration Statement on Form S-3  
Filed on May 15, 2024  
File No. 333-279433

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Mereo BioPharma Group plc (the “**Company**”) hereby requests that the Securities and Exchange Commission (the “**Commission**”) accelerate the effective date of the above-referenced registration statement on Form S-3 (the “**Registration Statement**”) so that the Registration Statement will be declared effective as of 4:00 p.m., Eastern Time, on May 22, 2024, or at such other time as the Company or its outside counsel, Mayer Brown LLP, may request via a telephone call to the staff of the Commission.

Once the Registration Statement has been declared effective, please orally confirm that event with David S. Bakst of Mayer Brown LLP at (212) 506-2551.

Thank you for your assistance in this matter.

Very truly yours,

MEREO BIOPHARMA GROUP PLC

By: /s/ Denise Scots-Knight

Name: Denise Scots-Knight

Title: Chief Executive Officer

Cc: David S. Bakst  
Mayer Brown LLP  
Christine Fox  
Charles Sermon  
Mereo BioPharma Group plc